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Abstract Membranoproliferative glomerulonephritis is an
uncommon kidney disorder characterized by mesangial cell
proliferation and structural changes in glomerular capillary
walls. It can be subdivided into idiopathic and secondary
forms, which are differentially diagnosed by a review of
clinical features, laboratory data, and renal histopathology.
Three types—I, II, and III—have been defined by pathologic
features. All three types are associated with hypocomplemen-
temia, but they manifest somewhat different mechanisms of
complement activation. Type II, also known as “dense deposit
disease”, is associated with the presence of C3-nephritic
factor. Membranoproliferative glomerulonephritis primarily
affects children and young adults, with patients presenting
with nephrotic or nephritic syndrome or with asymptomatic
renal disease. This type of glomerulonephritis often pro-
gresses slowly to end-stage renal disease, and it tends to recur
after renal transplantation, especially type II. The efficacy of
various forms of treatment remains controversial; however,
long-term steroid treatment seems to be effective in children
with nephrotic-range proteinuria. Improvement in renal out-
comeslargelyreliesontheevaluationofmoreselectiveagents
in carefully controlled studies.
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Introduction
The termmembranoproliferative glomerulonephritis(MPGN)
is often employed to denote a general pattern of glomerular
injury seen in a variety of disease processes that share a
common pathogenetic mechanism, rather than to describe a
single disease entity [1]. It encompasses forms of unknown
cause (idiopathic) and forms associated with systemic and
infectious disorders (Table 1). Mixed essential cryoglobuli-
nemia associated with chronic hepatitis C virus (HCV)
infection has now been implicated in a substantial number of
cases of what were previously thought to be idiopathic
MPGN [2].
Morphologically, MPGN is characterized by diffuse
mesangial cell proliferation and the thickening of capillary
walls due to subendothelial extension of the mesangium;
hence, the alternative term “mesangiocapillary glomerulo-
nephritis”. There are at least two (possibly three) distinct
morphologic types of MPGN, and all three are related to
complement activation (Fig. 1). Type I (classical MPGN),
the most common variant, is characterized by the presence of
subendothelial deposits of immune complexes associated
with activation of the classical complement pathway. Type II
MPGN (dense deposit disease), is a unique variant charac-
terized by the presence of additional intra-membranous
dense deposits. This type is known to be associated with a
serum immunoglobulin, C3 nephritic factor (C3NeF), that
stabilizes C3 convertase (C3bBb), thereby resulting in
persistent activation of the alternative complement pathway.
Type III MPGN, which some pathologists consider as a
morphologic variant of type I, is characterized by the
presence of additional subepithelial deposits.
Idiopathic MPGN is one of the least common types of
glomerulonephritis, accounting for approximately 4 and 7%
of primary renal causes of nephrotic syndrome in children
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in different parts of the world, but has shown a decline in
most developed countries. Interestingly, in Turkey and
Nigeria, MPGN has been reported as the most common
histopathologic subtype in children with nephrotic syn-
drome who underwent renal biopsy [4, 5]. All types of
MPGN typically have a slowly progressive clinical course.
Nonetheless, only 2.8% of end-stage renal disease (ESRD)
in children on dialysis and 3.3% of ESRD in pediatric renal
transplant recipients are caused by MPGN [6].
Fig. 1 Schematic depiction of
the complement system high-
lighting the different pathways
of complement activation in the
three types of membranoproli-
ferative glomerulonephritis
(MPGN). NeFt Nephritic factor
of the terminal pathway,
P properdin
Table 1 Classification of membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis Associated with systemic and infectious disorders
Idiopathic
Type I
Type II (dense deposit disease)
Type III
Secondary
Infectious diseases Viral: Hepatitis B and C, human immunodeficiency virus
Bacterial: shunt nephritis, visceral abscesses, infective endocarditis
Protozoal: quartan malaria, schistosomiasis, leprosy
Other: mycoplasma, mycobacteria
Systemic immune complex diseases Mixed cryoglobulinemia
Systemic lupus erythematosus
Scleroderma
Sjögren’s syndrome
Hereditary deficiencies of complement components
Hypocomplementemic urticarial vasculitis
Neoplasms Leukemias and lymphomas
Carcinomas
Light-chain disease and plasma cell dyscrasias
Chronic liver disease Chronic hepatitis
Cirrhosis
Miscellaneous Partial lipodystrophy
α1-Antitrypsin deficiency
Cystic fibrosis
Drugs (e.g. heroin, α-interferon)
Sarcoidosis
Sickle cell disease
Hemolytic uremic syndrome
Transplant glomerulopathy
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The pathogenesis of MPGN is not yet clearly under-
stood. It is believed that type I MPGN results from
chronic antigenemia and the generation of nephritogenic
immune complexes that preferentially localize to the
subendothelial spaces. The precise nature of the putative
antigen(s) in most patients with type I MPGN is
unknown; however, a specific pathogenic antigen can
sometimes be demonstrated in the glomerular lesions [7].
Recent studies have demonstrated the contribution of
innate immunity to both the generation of antibodies that
are deposited as immune complexes and to the local
inflammatory responses directed at the glomerular im-
mune deposits [8, 9]. The immune complexes activate the
complement system via the classical pathway, leading to
the generation of chemotactic factors (C3a, C5a) that
mediate the accumulation of platelets and leukocytes and
of terminal components (C5b-9) that directly induce cell
injury. Leukocytes release oxidants and proteases that
mediate capillary wall damage and cause proteinuria and a
fall of glomerular filtration rate. Cytokines and growth
factors released by both exogenous and endogenous
glomerular cells lead to mesangial proliferation and matrix
expansion [10].
The pathophysiologic basis for type II MPGN seems
to be the uncontrolled systemic activation of the
alternative pathway of the complement cascade [11, 12].
In most patients, loss of complement regulation is caused
by the C3 nephritic factor (C3NeF), an immunoglobulin
(Ig)G autoantibody that binds and prevents the inactiva-
tion of C3 convertase (C3bBb) of the alternative pathway,
thereby resulting in the perpetual breakdown of C3. A
further cause of type II MPGN is due to mutations in the
complement regulatory protein, factor H, or to autoanti-
bodies that impede factor H function, highlighting the role
of deregulated alternative complement pathway activity in
type II MPGN [12].
Type II MPGN may occur in association with two other
conditions, either separately or together: acquired partial
lipodystrophy (APD) and macular degeneration. The
abnormal activation of the alternative pathway of the
complement system is the common link to these seemingly
disparate diseases [13]. Acquired partial lipodystrophy is
associated with the presence of circulating C3NeF, which
can cause a complement-mediated lysis of adipocytes that
in turn produce high concentrations of factor D, also called
adipsin. Factor D cleaves factor B, activating the alternative
complement pathway. By analogy, C3NeF may cause
damage to glomerular cells that produce the complement.
Nonetheless, C3NeF can occur in apparently healthy
individuals and in patients with other types of glomerular
diseases. In addition, C3NeF does not always correlate with
the occurrence or progression of type II MPGN, suggesting
the role of other factors [12].
Complement perturbation in type III MPGN is thought
to be related to a slow-acting nephritic factor that
stabilizes a properdin dependent C5-convertase, (Cb3)
2BbP, activating the terminal pathway; hence, the term
nephritic factor of the terminal pathway (NeFt) [14]. This
nephritic factor has not been reported in healthy subjects,
unlike C3NeF. In addition, the deposits observed in renal
biopsies of patients with type III MPGN are closely
associated with the circulating nephritic factor-stabilized
convertase and with hypocomplementemia, suggesting
that NeFt is fundamental to the pathogenesis of type III
MPGN [15].
The mechanism of renal injury in HCV-associated
cryoglobulinemia remains elusive. An estimated 50–60%
of patients with chronic HCV infection develop type II
cryoglobulins, which are composed of a complex of an IgM
kappa monoclonal antibody with rheumatoid factor activity
directed against a polyclonal anti-HCV IgG. However, only
a minority (10–20%) of such patients with detectible
cryoglobulinemia have clinical manifestations of cryoglo-
bulinemic MPGN [2]. It is unclear why some cryoglobulins
are more pathogenic than others, or why cryoglobulins
deposit in the kidneys. Recognition of the components of
cryoprecipitates, which contain HCV core protein, by
circulating leukocytes and intrinsic glomerular cells leads
to the production of inflammatory mediators that charac-
terize the glomerular injury of cryoglobulinemic MPGN.
Clinical manifestations
Membranoproliferative glomerulonephritis primarily affects
children and young adults, with no sex predilection. In
children, MPGN is frequently idiopathic, whereas in adults,
MPGN is commonly associated with cryoglobulinemia and
HCV infection. Patients with MPGN may present in one of
four ways, as follows:
1. nephrotic syndrome (40–70%);
2. acute nephritic syndrome (20–30%);
3. asymptomatic proteinuria and hematuria detected on
routine urinalysis (20–30%);
4. recurrent episodes of gross hematuria (10–20%).
A respiratory tract infection may precede the diagnosis
in half of the patients. Hypertension is found at
presentation in one third of patients but occurs more
frequently with progressive disease. Renal dysfunction
occurs in >50% of patients. The incidence of anemia out
of proportion to the degree of renal failure is common
and is thought to be related to complement-mediated
lysis of red blood cells. Compared with adults, children
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to have renal insufficiency and hypertension [16].
The different types of MPGN cannot be distinguished
based on clinical presentation. However, the presence of
associated extra-renal manifestations, such as drusen or
APD, suggests type II MPGN. In contrast to drusen that
form in age-related macular degeneration, drusen in
individuals with MPGN II occur at an early age and often
are detectable in the second decade of life. Similarly, the
loss of subcutaneous fat in the upper half of the body in
APD usually precedes the onset of kidney disease by
several years.
Hypocomplementemia is a characteristic feature of all
types of MPGN, which is essentially the only cause of
idiopathic nephrotic syndrome that is associated with
hypocomplementemia. In type I MPGN and cryoglobuline-
mic MPGN, the classical pathway is preferentially activated
(low or normal C3, low C4 and CH50), while in type II
MPGN, the alternative pathway is activated (low C3,
normal C4 and low CH50), and in type III MPGN, the
complement profile typically reveals evidence of the
activation of both the alternative and terminal pathways
(low C3, normal C4 and low C5 through C9) [17]. The
serological detection of nephritic factors is quite useful in
distinguishing among the types of MPGN; however, apart
from C3NeF, which is positive in over 80% of patients with
type II MPGN and even more frequent in children, assays
for other nephritic factors are performed primarily in
research laboratories and are not widely available. The
clinical and laboratory evaluation of patients with suspected
MPGN is summarized in Table 2.
The natural history of MPGN is characterized by
spontaneous fluctuations of the severity of the clinical
picture, with very few cases of spontaneous, complete
remission. Children tend to have a more acute presentation
and a slower decline in renal function than adults.
Approximately 40% of patients progress to ESRD within
10 years of diagnosis. Features suggestive of an adverse
outcome include the nephrotic syndrome, renal dysfunction
at onset, and persistent hypertension. Type II MPGN is
associated with a worse prognosis, as is the presence of
chronic interstitial damage on renal biopsy [18].
Membranoproliferative glomerulonephritis may recur in
renal transplant recipients with a frequency of 20–30% for
type I and 80–90% for type II. The North American
Pediatric Renal Transplant Cooperative Study investigated
t h ei m p a c to ft y p eI IM P G Nr e c u r r e n c ei nal a r g e
population of pediatric renal transplant patients [19]. The
study indicated that recurrence had a significant negative
impact on renal allograft function and survival, contributing
to graft failure in 15% of recipients by 5 years post-
transplantation. No clear predictors of disease recurrence
were identified in the above-mentioned study.
Histopathology
Type I MPGN
The glomeruli often show a global increase in mesangial
cellularity and matrix with diffuse endocapillary prolifera-
tion. Infiltrating mononuclear leukocytes and neutrophils
also contribute to the glomerular hypercellularity. As a
consequence of these changes, the glomerular tufts appear
hyper-lobulated (Fig. 2b). Another distinctive feature of
MPGN is the diffuse thickening and duplication of the
glomerular basement membranes (GBM) that can be seen
with Periodic acid–Schiff and silver stains. This appearance,
also known as tram-tracking, splitting, or reduplication of the
GBM, results from the presence of subendothelial deposits
and the so-called “mesangial interposition” whereby mesan-
gial cells, infiltrating mononuclear cells, or even portions of
endothelial cells interpose themselves between the endothe-
lium and basement membrane, with new, inner GBM-like
material being laid down (Fig. 2b). Deposits can occasionally
be demonstrated in the subendothelial location by trichrome
staining. The proportion of cells to matrix varies with the
durationofthedisease.Inadvancedcases,lobularcentersmay
become completely sclerosed, simulating the Kimmelstiel–
Wilson nodules of diabetes. Glomerular crescents are
present in approximately 10% of cases and may occur in
both idiopathic and secondary forms [20]. The presence
of eosinophilic hyaline globules in capillary lumina
suggests mixed cryoglobulinemia and should be carefully
sought. The interstitium, tubules, and vessels show non-
specific changes that correlate with the severity of chronic
damage. Vasculitis affecting small and medium-sized renal
arteries is strongly associated with underlying cryoglobu-
linemic MPGN [21].
The most common immunofluorescence finding is
strongly positive staining for C3 and, less frequently,
for IgG and IgM, in a fine to course granular pattern
along the glomerular capillaries. This corresponds to the
prominent subendothelial deposits seen by electron
microscopy. Early complement components (C1q or C4)
and properdin are also frequently present. Occasionally
the C3 deposits are predominantly mesangial.
Electron microscopy (Fig. 3a) reveals an expanded
mesangium which contains cells, matrix, and often
electron-dense deposits. The subendothelial space is
widened and filled with mesangial cells and matrix
continuous with those in the centrilobular mesangial area
and with granular electron-dense deposits. The formation
of a “new basement membrane” is demonstrated under the
endothelial cell. There is an effacement of podocyte foot
processes and occasional subepithelial small electron-
dense deposits. The detection of microtubular structures
suggests cryoglobulinemia.
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The glomerular changes in type II MPGN can be quite
variable. Glomerular hypercellularity and lobulation, as in
type I MPGN, is seen in only 25% of all cases [22]. Thus,
the alternative term “dense deposit disease” is probably
more accurate than the designation type II MPGN as the
former emphasizes the pathognomonic feature of type II
MPGN, which is the presence of elongated, brightly
eosinophilic, variably refractile deposits within the GBM.
The deposits may be continuous and ribbon-like or
periodically interrupted, thereby having the appearance of
a “string of sausages” (Fig. 2c). On silver-stained speci-
mens, these intra-membranous deposits appear to be light
brown and surrounded by darker lines forming a double-
contour. Similar deposits may be seen in the tubular
basement membrane and Bowman’s capsule. Crescents
may be present.
Specimens studied by immunofluorescence microscopy
show staining for C3, usually in a linear or granular pattern
along the glomerular capillaries, and in the mesangium.
Immunoglobulin is not detected, indicating that the dense
deposits are not classic antigen–antibody immune com-
plexes. However, segmental IgM or less often IgG and
rarely IgA have been reported. Early complement compo-
nents are usually absent.
The key feature observed on electron microscopy
(Fig. 3b) is a layer of highly electron-dense material within
the lamina densa of the glomerular capillary basement
membrane that splits into two layers. Granular deposits of
similar dense material are usually present in the mesan-
gium. Similar deposits are also seen in some tubular
basement membranes and Bowman’s capsule.
Type III MPGN
This subtype of MPGN has some features in common with
those seen in type I MPGN, such as double contours of the
GBM and subendothelial deposits, together with wide-
spread subepithelial deposits similar to those seen in
membranous glomerulonephritis. However, hypercellularity
is often less prominent than in type I MPGN [23].
Immunostaining reveals a heavy granular pattern along
the glomerular capillary walls and mesangium for C3 and
sometimes IgG and IgM. Ultrastructural studies may reveal
multilayering of the basement membrane material and
complex disruption of the lamina densa by large dense
deposits.
Table 2 Evaluation of patients with suspected membranoproliferative glomerulonephritis (MPGN)
History
￿ Preceding upper respiratory tract infection
￿ Urinary symptoms; oliguria, hematuria, frothy urine, etc
￿ Symptoms of anemia; fatigue, pallor, etc
￿ Uremic symptoms; anorexia, vomiting, etc
￿ Symptoms suggestive of secondary MPGN; jaundice, joint pains, weight loss, etc
￿ Blood transfusion
Examination
￿ Blood pressure
￿ Presence of nephrotic syndrome
￿ Stigmata of chronic liver disease
￿ Features of cryoglobulinemia; acrocyanosis, peripheral neuropathy etc
￿ Ophthalmic examination for drusen
￿ Features of partial lipodystrophy
￿ Urine dipstick analysis
Investigations
￿ Biochemistry, creatinine clearance, 24-h urinary protein or spot urine protein/creatinine ratio, immunoglobulin electrophoresis, serum
cholesterol, lactate dehydrogenase, angiotensin-converting enzyme, α1-antitrypsin
￿ Hematology: full blood count, clotting screen
￿ Immunology: complements (C3,C4, CH50), C3NF, ANA, ANCA, ENA, rheumatoid factor, cryoglobulins
￿ Microbiology: HCV, HBV, HIV, blood cultures
￿ Radiology: chest X-ray, renal ultrasound scan
￿ Histopathology: kidney biopsy
NF, Nephritic factor; ANA, antinuclear antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; ENA, epithelial neutrophil-activating peptide;
HC(B)V, hepatitis virus C(B); HIV, human immunodeficiency virus
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The efficacy of the various therapeutic regimens tried in
MPGN is difficult to assess because of the small patient
numbers and short-term nature of published controlled
trials; the larger trials carried out to date have been
uncontrolled [24]. Moreover, most trials include patients
with all three types of MPGN in different proportions,
making the analysis of treatment results more difficult.
Treatment strategies for idiopathic MPGN are controversial
and have included corticosteroids, immunosuppressives,
antiplatelet regimens, plasma exchange and biologic agents.
Corticosteroids
Both retrospective and prospective studies have demon-
strated the beneficial effect of alternate-day steroid therapy
on renal survival in pediatric patients with MPGN. Of
these, a prospective, multicenter, randomized trial was
conducted by the International Study of Kidney Disease
in children (ISKDC) [25]. Eighty children, predominantly
with type I MPGN were randomized to receive either
40 mg/m
2 of prednisone every other day or placebo for a
mean duration of treatment of 41 months. Criteria for
admission included heavy proteinuria and a glomerular
filtration rate (GFR) ≥70 ml/min/1.73 m
2. Treatment failure
(30% increase in serum creatinine) occurred less frequently
(40%) in patients treated with prednisone than in those who
received placebo (55%), and 61% of the treatment group
versus 12% of the placebo group had stable renal function
at the end of the study. The use of such a protracted course
of steroid medication is not without adverse effects,
particularly on bone growth. Non-nephrotic children may
forego steroid treatment without compromising long-term
kidney function [26]. While corticosteroid therapy seems to
be effective in children, there is no convincing published
evidence that steroids are effective in modifying disease
activity or disease progression in adults with idiopathic
MPGN.
Cyclophosphamide
Inonestudy[27], 19 pediatric and adult patients with MPGN
were treated with an intensive and prolonged regimen of
Mesangial
interposition
Subendothelial
deposits
Mesangial
deposits
Intramembranous
deposits
a
b
c
Glomerular
basement
membrane
Foot
processes
Mesangial
cell
Podocyte
Endothelial
cell
Fig. 2 In the normal glomerulus (a), the capillary loops are open, the
mesangial areas have no more than three nuclei each, and the foot
processes are intact, without any deposits or proliferation. In type I
MPGN (b), the glomerulus appears to be lobulated due to extensive
endocapillary proliferation, and the glomerular basement membrane
has a split appearance as a result of the mesangial interposition and
subendothelial deposits. In type 2 MPGN (c), the capillary walls
appear to be thickened by dense deposits in a ribbon-like pattern, and
the mesangial area also contains dense material

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phosphamide. Of the 19 patients, 15 achieved complete
remission and three achieved a partial remission. Based on
these results, the researchers concluded that cyclophospha-
mide is effective in inducing remission and halting the
progression of MPGN to ESRD. There are as yet no studies
to suggest whether the addition of cyclophosphamide to a
prednisolone therapeutic regimen provides any added advan-
tage. Nonetheless, cyclophosphamide is generally recom-
mended in patients with rapidly progressive renal failure or a
recent deterioration in renal function, especially those with
crescents on histopathology.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is an anti-proliferative
agent that is being increasingly used for treating patients
with various forms of immune-mediated renal disease. In
idiopathic MPGN, preliminary studies suggest that the
combination of MMF and corticosteroid can, in the short
term, reduce proteinuria and may preserve renal function
[28, 29].
Cyclosporine
The efficacy of cyclosporine was tested in a recent trial
involving 18 patients with refractory MPGN who also
received small doses of prednisolone (0.15 mg/kg/day).
Long-term reductions in proteinuria with preservation of
renal function was observed in 17 of the patients, suggest-
ing that cyclosporine can be considered in corticosteroid-
resistant primary MPGN [30].
Plasma exchange
Plasma exchange has not been studied in a controlled
manner. Success has been reported for the treatment of type
II MPGN recurring after transplantation [13]; however,
there are no long-term data on graft survival. There is some
evidence that patients with Factor H deficiency may benefit
from plasma exchange [31, 32].
Antiplatelet therapy
The rationale for antiplatelet therapy is that platelet
consumption is increased in MPGN and that platelets may
play a role in glomerular injury. The combination of aspirin
(975 mg/day) and dipyridamole (275 mg/day) was found to
have useful effects on renal function in a randomized
double-blind placebo-controlled trial in 40 patients with
idiopathic MPGN, including children [33]. However, these
same authors retracted this conclusion in a subsequent
study [34]. Another study reported a clinically significant
reduction in proteinuria in patients treated with aspirin
(500 mg/day) and dipyridamole (75 mg/day), but very little
change in the GFR [35].
Possible future therapeutic strategies
Anti-inflammatory agents, such as corticosteroids, may
have useful effects in treating MPGN, but their non-
specific nature and adverse effects mean that a high price
is paid for any beneficial effect on the renal lesion. More
selective forms of anti-inflammatory therapy are becoming
available [36], and these are aimed at individual pro-
inflammatory mediators, such as tumor necrosis factor
(which can be neutralized with specific antibodies) or
interleukin (IL)-1 (the effect of which can be abrogated
using soluble IL-1 receptor antagonist). Therapies which
inhibit complement activation by both the classical and
alternative pathways, such as eculizumab (an anti-C5
antibody designed to decrease C5a-mediated glomerular
damage), should also be considered. Another attractive
strategy which merits study is to reduce C3NeF using
Fig. 3 Electron micrographs
show subendothelial deposits
with intermesangial interposi-
tion in type I MPGN (a) and
intramembranous dense deposits
in type II MPGN (b). Original
magnification: a ×25,000,
b ×7000
Pediatr Nephrol (2010) 25:1409–1418 1415Idiopathic MPGN p
24 hr urinary protein or 
urine protein/creatinine ratio
Creatinine clearance
Proteinuria > 3g/d Rapidly progressive renal Chronic renal failure
Proteinuria <3g/d  ± Renal impairment
    
failure                     (children and adult)
+ Normal renal function
( hild d d lt )
(children and adults)          Conservative 
c ren an  a u s)
No specifictreatment
Pulse methylprednisolone
followed by tapering course
management
Renaltransplantation   
Follow up every 3 months
      
of oral prednisolone+ oral 
l h h id MMF
 
      
Control hypertension and  Child: Trial of steroid Adult:  Trial of aspirin 
cyclop osp am e or    
×3mo n th s
proteinuriawith ACEI or ARB 40mg/m2 alternate days 
×6 12 months
500mg ± dipyridamole
75mg tds ×6 12 months
 
Consider plasma exchange -   -      
Acute graft failure 
secondary to 
recurrence
No response
 
Consider plasma
No response Consider corticosteroids ±
immunosuppressive
     
exchange
Consider cyclosporine + low 
dose steroids Alternatively treat as proteinuria dose  ,    
< 3g/d
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1416 Pediatr Nephrol (2010) 25:1409–1418rituximab (a chimeric IgG1 monoclonal antibody that
specifically targets the CD20 surface antigen expressed on
B lymphocytes). The improved understanding of the
pathogenesis of MPGN is likely to result in the identifica-
tion of future agents that will modify the intense cellular
proliferation and immune deposition seen in this glomerular
disease.
In summary, the therapeutic options in idiopathic
MPGN depend on the level of proteinuria and kidney
failure, as shown in Fig. 4. Management of patients with
hepatitis C-associated cryoglobulinemic MPGN is also
dictated by the severity of proteinuria and renal dysfunc-
tion [37], necessitating two distinct approaches, as shown
in Fig. 5. In all patients, the empiric use of angiotensin-
converting enzyme inhibitors or angiotensin II receptor
antagonists, as drugs of first choice to treat hypertension
and decrease proteinuria, is a common practice that may
retard the progression of renal disease. Treatment of
recurrent MPGN in renal transplant is uncertain, but
plasma exchange may be useful in patients whose renal
function deteriorates rapidly [13], whereas rituximab
seems to be an effective treatment in the presence of
cryoglobulinemia [2, 37]. Lastly, improvement in renal
outcomes for patients with MPGN largely relies on the
evaluation of more selective agents in future studies.
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Questions:
(Answers appear following the question list)
1. Which of the following statements regarding the
prevalence of MPGN is true?
a) MPGN is more common in Europe and North
America
b) MPGN usually affects children and young adults
with a male to female ratio of 3:1
c) MPGN accounts for approximately 5% of the
primary renal causes of nephrotic syndrome in
children and adults
d) MPGN is a common cause of ESRD in children
2. Which of the following statements regarding C3NeF is
correct?
a) C3NeF is an IgM autoantibody
b) C3NeF can be found in healthy subjects
c) C3NeF prevents the inactivation of C3 convertase
(C3bBb) by factor I
d) C3NeF is a surrogate marker of disease progression
3. Which of the following histological features is the most
characteristic of MPGN?
a) Duplication of the glomerular basement membrane
b) Crescent formation
c) Effacement of the podocyte foot process
d) Positive staining for C4 along the glomerular
capillaries
4. Which of the following statements regarding the
recurrence of MPGN in kidney transplantation is true?
a) More common in type I MPGN
b) Is usually benign
c) Nephrotic-range proteinuria is a risk factor for
recurrence
d) Can morphologically resemble transplant
glomerulopathy
5. Which of the following regarding the treatment of
idiopathic MPGN is true?
a) The rarity of MPGN makes the randomized
controlled study design easy to implement
b) There is a good evidence that the combination of
aspirin and dipyridamole slows the progression of
the disease
c) Steroid therapy has been proven effective for
children but not for adults
d) Cyclosporine is generally recommended in patients
with rapidly progressive renal failure
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